MPG.eBooks - Description: Clinical review report: AbobotulinumtoxinA (Dysport therapeutic)

Cover Image

Read Now

Clinical review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.)

The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the treatment of upper limb spasticity (ULS) in adults

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health November 2017, 2017
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Canada Muscle Spasticity / Drug Therapy Upper Extremity / Physiopathology Botulinum Toxins, Type A / Therapeutic Use Botulinum Toxins, Type A / Adverse Effects
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534668
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the treatment of upper limb spasticity (ULS) in adults
Physical Description:	1 PDF file (123 pages) illustrations